Novel therapeutics in development for the treatment of stimulant-use disorder.

Autor: Young EJ; Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL, USA; Department of Neuroscience, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL, USA; Myosin Therapeutics, Jupiter, FL, USA., Radnai L; Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL, USA; Department of Neuroscience, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL, USA., Prikhodko V; Myosin Therapeutics, Jupiter, FL, USA., Miller CA; Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL, USA; Department of Neuroscience, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL, USA. Electronic address: CMiller@scripps.edu.
Jazyk: angličtina
Zdroj: Current opinion in neurobiology [Curr Opin Neurobiol] 2024 Aug; Vol. 87, pp. 102898. Date of Electronic Publication: 2024 Aug 02.
DOI: 10.1016/j.conb.2024.102898
Abstrakt: Misuse and accidental overdoses attributed to stimulants are escalating rapidly. These stimulants include methamphetamine, cocaine, amphetamine, ecstasy-type drugs, and prescription stimulants such as methylphenidate. Unlike opioids and alcohol, there are no therapies approved by the US Food and Drug Administration (FDA) to treat stimulant-use disorder. The high rate of relapse among this population highlights the insufficiency of current treatment options, which are limited to abstinence support programs and behavioral modification therapies. Here, we briefly outline recent regulatory actions taken by FDA to help support the development of new stimulant use disorder treatments and highlight several new therapeutics in the clinical development pipeline.
Competing Interests: Declaration of Competing Interest Erica Young, Victor Pridhoko and Courtney Miller have an equity interest in Myosin Therapeutics. Laszlo Radnai has nothing to disclose.
(Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE